Bottom line: “Kikuchi–Fujimoto disease, or Kikuchi’s disease, also known as histiocytic necrotizing lymphadenitis, is a rare, benign, self‐limiting condition characterized by cervical lymphadenopathy and fever….symptoms usually resolve spontaneously within 1–4 months. However, cervical lymphadenopathy can persist for up to 6 months and even 1 year. There is a possibility of recurrence, yet rates of only 3–4% have been reported. The treatment of Kikuchi’s disease is primarily supportive and aims to facilitate the relief of symptoms with the use of analgesics, antipyretics, and rest. In a more severe or protracted disease course, short‐duration oral corticosteroid therapy is the treatment of choice. There are no specific guidelines regarding the dosage or length of treatment. Hydroxychloroquine is another therapeutic option that has been used to achieve rapid clinical improvement in Kikuchi’s disease. The safety profile of hydroxychloroquine may make it a better alternative to long‐term, high‐dose corticosteroids as it has fewer adverse effects. Despite a lack of recommendation, intravenous immunoglobulin, given its immunomodulatory nature, has also been used successfully in patients with severe disease. The mortality rate with Kikuchi’s disease was calculated to be 2.1%. Patients diagnosed with Kikuchi’s disease should be subject to close long‐term monitoring for the possible development of SLE [systemic lupus erythematosus]. Kikuchi’s disease can precede the onset of SLE by years.”1 Review articles provides several histopathological and dermatological images of patients with the condition.
Reference: Mathew LM, Kapila R, Schwartz RA. Kikuchi-Fujimoto disease: a diagnostic dilemma. Int J Dermatol. 2016 Oct;55(10):1069-75. doi: 10.1111/ijd.13314. Epub 2016 May 21.